Reports
Biosimilars as a sustainable option for the health system in Argentina
The COVID-19 pandemic in Argentina has raised questions about its impact on highly complex medical treatments, which, because they are imported, are costly to the social security system, to the point that they make coverage unviable for many.
Comparison of authorization requirements for biological and biosimilar medicines
The development of biosimilar medicines presupposes a paradigm shift from the traditional model used with an innovative medicine. Meanwhile, for a new molecular entity, the evidence for its development is based on generating data confirming its safety and efficacy.
Use of biosimilars generates savings in the Spanish health budget of 2021
It is estimated that the national health system (Sistema Nacional de Salud, SNS) will be able to save €930 million due to the use of biosimilars in 2021, according to the results of the Budgetary Impact Analysis of Biosimilar Medicines in the SNS of Spain (2009–2022) [1].
Five main barriers to developing biosimilars
According to Dr Ash Ramzan, principal consultant at Woodley BioReg, there are five main barriers preventing biosimilars from reaching their full potential.
Position of CAEME on biological and biosimilar drugs in Argentina
The pharmaceutical companies that comprise the Argentine Chamber of Medicinal Products (Cámara Argentina de Especialidades Medicinales, CAEME) consider that biosimilar medicines are necessary for the sustainability of the healthcare system and patient access to effective treatment.
A few drugs account for most of Medicare Part B spending
Findings from an analysis carried out by KFF of Medicare* spending in 2019 found that most of the Medicare Part B** spending on drugs was on a relatively small number of drugs [1]. KFF is a non-profit organization that provides independent information on national health issues.
A broader and stronger generic drug market is promoted in Mexico
During a press conference held on 14 November 2020, ‘A new generic medicines market’ strategy was revealed, with which ’the Health and Economic Secretaries will strengthen the companies producing generic medicines, through the linking mechanisms and technological tools, based on the principles of innovation, transparency, competitiveness and legality’ fostering firmly a wider and solid generic medicines market, for the benefit of Mexican nationals.
A few drugs account for most of Medicare Part D spending
An analysis of Medicare* spending in 2019 was recently carried out by KFF, a non-profit organization that provides independent information on national health issues. The analysis found that most of the Medicare Part D** spending on drugs was on a relatively small number of drugs with only one manufacturer and without generic or biosimilar competitors [1].
A small number of drugs account for most of Medicare spending
A new analysis carried out by KFF, a non-profit organization that provides independent information on national health issues, has found that a relatively small share of drugs without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in the US Medicare* system in 2019 [1].
Rheumatologists are prescribing more biosimilars
Although the use of biosimilars for the treatment of autoimmune diseases varies widely by geographical region, the trend is that rheumatologists are prescribing more biosimilars.